TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
MedAdvisor Limited ( (AU:MDR) ) has shared an update.
MedAdvisor Limited announced at its 2025 Annual General Meeting that despite a substantial statutory loss due to a non-cash impairment of intangible assets in its U.S. business, the company has taken decisive steps to position itself for a sustainable future. The sale of its Australian and New Zealand operations for $35 million, with a potential earnout of $7.4 million, has allowed MedAdvisor to repay all debt obligations, leaving it debt-free and in a stronger financial position to consider future strategic options.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
More about MedAdvisor Limited
MedAdvisor Limited (ASX: MDR) is a leader in pharmacy-driven patient engagement solutions, providing personalized patient experiences to simplify the medication journey. Utilizing THRiV, a cloud-based, AI-enabled platform, MedAdvisor enhances pharmacy workflow and patient engagement. The company collaborates with over 34,000 pharmacies across the US, reaching more than two-thirds of the population.
Average Trading Volume: 1,465,632
Technical Sentiment Signal: Sell
Current Market Cap: A$12.69M
Learn more about MDR stock on TipRanks’ Stock Analysis page.